GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » Scaled Net Operating Assets
Switch to:

Incyte (NAS:INCY) Scaled Net Operating Assets

: 0.24 (As of Sep. 2022)
View and export this data going back to 1993. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Incyte's operating assets for the quarter that ended in Sep. 2022 was $2,533 Mil. Incyte's operating liabilities for the quarter that ended in Sep. 2022 was $1,241 Mil. Incyte's Total Assets for the quarter that ended in Jun. 2022 was $5,319 Mil. Therefore, Incyte's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2022 was 0.24.


Incyte Scaled Net Operating Assets Historical Data

The historical data trend for Incyte's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Scaled Net Operating Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.23 0.21 0.25 0.41

Incyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Scaled Net Operating Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.35 0.28 0.28 0.24

Competitive Comparison

For the Biotechnology subindustry, Incyte's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte Scaled Net Operating Assets Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Incyte's Scaled Net Operating Assets falls in comparison to its industry or sector. The grey bar indicates the Scaled Net Operating Assets's extreme value range as defined by GuruFocus.



Incyte Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Incyte's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2021 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2021 )
=(Operating Assets (A: Dec. 2021 )-Operating Liabilities (A: Dec. 2021 ))/Total Assets (A: Dec. 2020 )
=(2585.16-1118.527)/3560.918
=0.41

where

Operating Assets(A: Dec. 2021 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4933.352 - 2348.192
=2585.16

Operating Liabilities(A: Dec. 2021 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1163.348 - 31.632 - 13.189
=1118.527

Incyte's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2022 )
=(Operating Assets (Q: Sep. 2022 )-Operating Liabilities (Q: Sep. 2022 ))/Total Assets (Q: Jun. 2022 )
=(2533.092-1241.483)/5319.035
=0.24

where

Operating Assets(Q: Sep. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5510.214 - 2977.122
=2533.092

Operating Liabilities(Q: Sep. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1283.563 - 30.476 - 11.604
=1241.483

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Incyte's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (NAS:INCY) Business Description

Incyte logo
Industry
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Susanne Schaffert director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Thomas Tray officer: Principal Accounting Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Edmund Harrigan director
Michael James Morrissey officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Jonathan Elliott Dickinson officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Christiana Stamoulis officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Maria E Pasquale officer: EVP & General Counsel C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Vijay K Iyengar officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Steven H Stein officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul Trower officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142

Incyte (NAS:INCY) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership